Roche's Ventana Medical Systems has submitted its companion diagnostic test for ALK1-positive lung cancer for FDA approval, inching the company closer to full regulatory approval for the product and helping it gain ground in a fiercely competitive cancer diagnostics market.
When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.
Roche has signed a deal to trade up to €470 million ($545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular atrophy.
A fresh wave of biopharma companies are partnering and investing in genome sequencing companies to integrate their data into the drug development process. The latest deal on this front pairs Roche with startup Human Longevity.
Scientists in Canada say they have drilled down into the massive data files from the development effort for cholesterol drug dalcetrapib and found that a subset of patients with the right genetic profile benefited greatly from the drug. And now they plan to follow up with a new study in an effort to revive the long-dead drug.
SAN FRANCISCO--More than a few presentations at the JP Morgan Healthcare conference this week sought to address the future of next-generation sequencing, particularly with the huge waves of related news.
Following through on its sweeping return to antibiotics R&D, Roche has agreed to pay up to $750 million to get its hands on an early-stage drug that helps existing treatments battle drug-resistant infections.
Roche is throwing the full weight of its global rep and more than $1 billion behind Foundation Medicine's ambitious sequencing technology, designed to tailor cancer treatment to particular patients and guide development of new cancer drugs.
Roche is shelling out $1 billion plus milestone payments for a majority share in Foundation Medicine, bolstering its diagnostics offerings for cancer and continuing its dealmaking streak.
Roche is throwing the full weight of its global rep and more than a billion dollars behind Foundation Medicine's ambitious sequencing technology for guiding the personalized treatment of cancer as well as the development of new oncology meds. The pharma giant has wrapped a deal to buy up a majority stake in the molecular diagnostics company for $780 million at $50 a share--a premium rate that's more than twice Friday's close of $23.93.